

A Synthesis of 11 β ,18,21-Trihydroxypregn-4-ene-3,20-dione (‘18-Hydroxy-corticosterone’)

By DAVID N. KIRK* and MARUTHIANDAN S. RAJAGOPALAN

(Medical Research Council Steroid Reference Collection, Chemistry Department, Westfield College, Hampstead, London NW3 7ST)

Summary 3 β -Acetoxypregn-5-ene-11,20-dione has been converted through 3 β -acetoxy-18,20-epoxy-20-hydroxypregn-5-en-11-one and ‘11 β ,18-dihydroxy-progesterone’ into ‘18-hydroxy-corticosterone.’


11 β ,18,21-TRIHYDROXYPREGN-4-ENE-3,20-DIONE (‘18-hydroxy-corticosterone’), which exists in the hemiacetal form (**1**), has been known for over a decade as one of the biosynthetic precursors of aldosterone.¹ A synthesis of racemic 18-hydroxy-corticosterone was reported in 1961 by the CIBA group,² but supplies of the natural enantiomer, required in medical and biochemical investigations, have had to be obtained by fungal^{3,4} or adrenal incubation⁵ of suitable steroids, no chemical synthesis having been reported. We now describe a synthesis from 3 β -acetoxy-pregn-5-ene-11,20-dione (**2**), based in part on our recent preparation of 18,21-dihydroxypregn-4-ene-3,20-dione (‘18-hydroxy-deoxycorticosterone’).⁶

3 β -Acetoxypregn-5-ene-11,20-dione (**2**) (Upjohn Co., Kalamazoo) was reduced with NaBH₄ in MeOH at 0 °C to give the 20 β -alcohol (**3**), which was irradiated in cyclohexane containing Pb(OAc)₄ and iodine (‘hypoiodite’ reaction⁷) to give its 18-iodo-derivative. The crude 20-hydroxy-18-iodo-compound was oxidised with Jones’ reagent in the usual way^{6,7} to give the 18-iodo-20-ketone;


silver ion-assisted hydrolysis then gave the hemiacetal (**4**) [m.p. 171–174 °C (from acetone–hexane), ν_{\max} 3522, 1722, 1699, 1669, 1245, and 1042 cm⁻¹; τ (CDCl₃) 8.82 (s, 10 β -Me), 8.50 (s, 21-H₃), 7.97 (s, AcO), 6.37 (s, 18-H₂), *ca.* 5.32 (m, 3 α -H), and *ca.* 4.6 (m, 6-H)], isolated by chromatography on silica gel. Gradient elution with benzene containing up to 7% of Et₂O gave compound (**2**) and by-products. The hemiacetal (**4**) was obtained by increasing the amount of Et₂O from 7 to 10%. For optimum yield of the hemiacetal (12.5%), determined from n.m.r. and i.r. spectra of final products from a series of reactions, it was necessary to use a molar ratio (steroid:iodine) of 1.0:0.9, instead of 1.0:0.55 as for similar reactions in the 11-deoxy series.

To permit selective reduction of the 11-oxo-group, the hemiacetal was converted into the corresponding 20-methoxy compound (**5**) (88%) [m.p. 152–154 °C, ν_{\max} (KBr) 1723, 1709, 1668, 1245, 1041, and 865 cm⁻¹; τ (CDCl₃) 8.85 (s, 10 β -Me), 8.65 (s, 21-H₃), 7.98 (s, AcO), 6.83 (s, OMe), 6.66, 6.37 (dd, *J* 10 Hz, 18-CH₂), *ca.* 5.4 (m, 3 α -H), and 4.65 (m, 6-H)] by methanolic HCl. [Hemiacetal (1.12 g) in anhydrous MeOH (50 ml), treated with HCl-saturated MeOH (0.1 ml) for 10 min at room temperature]. Reduction of the 11-oxo group with NaBH₄ in alkaline solution (tetrahydrofuran–EtOH 1:1) gave the 3 β ,11 β -diol (**6**) (ν_{\max} 3440 and 1650 cm⁻¹), which, without

purification, was converted by Oppenauer oxidation [cyclohexanone and $\text{Al}(\text{OPr}^i)_3$ in toluene] into '11 β ,18-dihydroxy progesterone' [isolated by p.l.c. as the hemiacetal (7), 36%



- (1) R = OH
 (7) R = H
 (8) R = OAc
 (2) R = O
 (3) R = β -OH, α -H



- (4) R¹ = Ac, R² = O, R³ = H
 (5) R¹ = Ac, R² = O, R³ = Me
 (6) R¹ = H, R² = β -OH, R³ = Me

from (5); ν_{max} 3420, 1662, 1615, 1162, and 1039 cm^{-1} , τ (CDCl_3) 8.59 and 8.53 (s, s, 10 β and 20-Me), 6.24 and 5.73 (dd, J 10 Hz, 18-H₂), 5.62 (m, $W_{\frac{1}{2}}$ ca. 7 Hz, 11 α -H), and 4.32 (s, 4-H)]. This compound is extremely sensitive to aqueous acids, which rapidly convert 11 β ,18-diols into 11 β ,18-ethers,^{2,4,8} recognised by relatively low polarity (t.l.c.) and by the i.r. absorption (ν_{max} 1705 cm^{-1}) of the regenerated 20-oxo-group, and by n.m.r. characteristics.⁹ The Oppenauer mixture was therefore worked up by

extraction with aqueous sodium potassium tartrate to remove aluminium compounds in an alkaline-buffered medium, and cyclohexanone was removed as completely as possible under reduced pressure rather than by steam distillation. (The formation of 11 β ,18-ethers frustrated an alternative approach to 18-hydroxy-corticosterone *via* the 3-ethylene acetal of 11-oxoprogesterone; the hypiodite reaction was also less satisfactory in this series.¹⁰)

To minimise 11 β ,18-ether formation during 21-acetoxylation, solvent-free 11 β ,18-dihydroxyprogesterone, in the hemiacetal form (7), was treated with solid $\text{Pb}(\text{OAc})_4$ followed *at once* by anhydrous AcOH. After swirling for 5 min to dissolve the reactants, the product was extracted with ether, which was washed neutral, dried, and evaporated to give crude 18-hydroxy-corticosterone 21-acetate (8) as a gum, τ (CDCl_3) 8.57 (s, 10 β -Me), 7.67 (s, AcO), 6.5–5.9 (m, 18-H₂), 5.72 (s, 21-H₂), 5.53 (m, $W_{\frac{1}{2}}$ ca. 8 Hz, 11 α -H), and 4.27 (s, 4-H). Alkaline hydrolysis of the 21-acetate with 0.1 M-NaOH in aqueous 90% MeOH under reflux for 30 min gave 18-hydroxy-corticosterone (1), purified by preparative t.l.c. (on Merck Kieselgel, HF 254; multiple development with benzene-Et₂O, 4:1) and crystallisation from acetone-hexane containing a trace of Et₃N [m.p. 148–150 °C (*cf.* m.p. 163–164 °C or 170 °C reported² for the racemate), ν_{max} (KBr) ca. 3400 br, 1661 and 1614 (4-en-3-one), 1281, 1230, 1061, 1040, 1032, 1018–998 br, and 895 cm^{-1}].

This route, and method of purification, avoids the formation of the useless dimer, which can result from contact with acid, or apparently from fermentation procedures for the preparation of 18-hydroxy-corticosterone.⁴ The product was identical with a sample provided by G. D. Searle and Co. Ltd. The identity was further confirmed by a mass spectral study, kindly carried out by Dr. C. J. W. Brooks, Glasgow; details will be given in our definitive paper, following work now in progress to optimise yields in the later stages of the synthesis.

(Received, 19th November 1975; Com. 1296.)

¹ J. R. Pasqualini, *Nature*, 1964, **201**, 501.

² J. Schmidlin and A. Wettstein, *Helv. Chim. Acta*, 1961, **44**, 1596.

³ P. B. Raman and F. G. Péron, *Steroids*, 1965, **5**, 249.

⁴ E. Kondo, T. Mitsugi, and K. Tori, *J. Amer. Chem. Soc.*, 1965, **87**, 4655.

⁵ S. Ulick and K. Kush, *J. Amer. Chem. Soc.*, 1960, **82**, 6421; F. G. Péron, *Endocrinology*, 1962, **70**, 386; A. G. Fazekas and K. Kokai, *Steroids*, 1967, **9**, 177.

⁶ D. N. Kirk and M. S. Rajagopalan, *J.C.S. Chem. Comm.*, 1974, 145; *J.C.S. Perkin I*, 1975, 1860.

⁷ Ch. Meystre, K. Heusler, J. Kalvoda, P. Wieland, G. Anner, and A. Wettstein, *Helv. Chim. Acta*, 1962, **45**, 1317.

⁸ J. Schmidlin and A. Wettstein, *Helv. Chim. Acta*, 1959, **42**, 2636.

⁹ K. Tori, T. Tomita, H. Itazaki, M. Narisada, and W. Nagata, *Chem. and Pharm. Bull. (Japan)*, 1963, **11**, 956.

¹⁰ M. Hossain, D. N. Kirk, and M. S. Rajagopalan, unpublished work.